Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia

Drug (Brand / Generic)

Kymriah™ / tisagenlecleucel

Developers

Penn and Novartis

Therapy Class

Chimeric antigen receptor T-cell (CAR-T) therapy

Current Indication

Acute lymphoblastic leukaemia (ALL), B-cell lymphoma

Market Sector

Oncology

Development Status

Approved in the US, Europe
Expand
Close
Close
Close

Go Top